Möchten Sie immer auf dem neuesten Stand bleiben?

Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease

Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026

White Oak, Md., May 11, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is soliciting input on efforts with respect to drug repurposing to help address unmet...

Angelini Pharma has entered into a definitive agreement to acquire Catalyst Pharmaceuticals.

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May ...

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.

CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions

Agios announces first quarter 2026 financial results and provides business update.

CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...

Dublin, April 28, 2026 (GLOBE NEWSWIRE) -- The "KCNQ2 Developmental and Epileptic Encephalopathy Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035" report has been...